Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

What makes you think so?
First it was the anti-fungal connection:
"On July 22, 2020, Innovation Pharma announced the Company granted licensing rights to Fox Chase Chemical Diversity Center, Inc. (FCCDC) for antifungal technology, making it eligible to receive a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties. FCCDC has since licensed the antifungal technology to Basilea Pharmaceutica AG."
http://www.ipharminc.com/collaborations?rq=basilea
Big Score......$18K.
Then....
"Basilea has completed the profiling of a lead compound from a recently in-licensed preclinical program of broad-spectrum antifungals with a new mode of action. The candidate did not meet Basilea’s stringent criteria for progressing into the development stage and the company decided to return the program to the licensor."
https://www.basilea.com/news#news_1411

Was the candidate that did not meet Basilea’s stringent criteria part of the Fox offering from the IPIX menu? Wonder if that will be mentioned in the 10-Q (due on Valentine's Day).
A hint may come from whether the underlined language from the last 10Q is repeated:
"On May 3, 2022, the Company received payment of $18,000 from FCCDC based on FCCDC’s third-party license of broad-spectrum anti-fungals and a separate agreement between the Company and FCCDC. Some of the preliminary data used in the FCCDC research program had been obtained as part of an earlier collaboration with the Company supported by funding from the National Institutes of Health. Additional payments from FCCDC to the Company may also be made in the future."


Now I guess you're pinning your hopes on B-ABSSSI.....
"A key focus for growing shareholder value will be the in-licensing or acquisition of new anti-infective assets in FY23"
....a candidate that had its Phase 2 results available for Basilea or any other pharma to consider since 2015.
Let me guess....Leo is just waiting for the right offer? How long does one wait when funds are almost gone?
"We expect to incur further losses in the development of our business and have been dependent on funding operations from inception. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives."
While that may be boilerplate language for non-revenue producing drug developers, in IPIX's case it is also TRUE.

"Brilacidin is a good fit for Basilea objectives."
Fact is that brilacidin needs to be a good fit for some company's objectives and soon.